Clinical Trials
15 trialsNCT02834013 2026-05-13
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT03737734 2026-04-06
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Phase NA Active not recruiting
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT03886181 2025-12-08
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Phase NA Terminated
NCT05859074 2025-12-03
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT03889899 2025-12-02
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT04540588 2025-12-02
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
Alpha Tau Medical LTD.
Phase NA Completed
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT04534127 2025-02-07
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT05329792 2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2 Unknown
NCT03775525 2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1 Unknown
NCT02507076 2015-07-23
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
Albert Einstein College of Medicine
Phase NA Withdrawn
NCT01609179 2012-11-14
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
Infinity Pharmaceuticals, Inc.
Phase NA Completed
NCT00023790 2011-08-24
Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin
Case Comprehensive Cancer Center
Phase 1 Terminated